Antidote Founder and CEO to Present at DPharm Conference

We are providing the patient connections and matching technology so that finding a trial becomes as straightforward as finding a flight.” Pablo Graiver, CEO

Antidote Technologies’ Founder and CEO, Pablo Graiver, will present “Clinical Trial Matching – Next Generation” at the 7th Annual DPharm: Disruptive Innovations to Advance Clinical Trials conference in Boston, which begins today. Antidote is the first clinical trial matching platform that connects patients to the right trials and helps researchers design trials to maximize participation.

The talk will be held at 12:15 pm ET on Friday, September 8, 2017. Joining Graiver in discussion will be Ed Godber, Antidote’s Entrepreneur-in-Residence and former Executive Vice President and General Manager of PatientsLikeMe Health. Together, Graiver and Godber will discuss the evolution of patient engagement for clinical trials and the growing necessity for a whole new approach.

“On the web, millions of people are starting to inquire about what’s coming next in medical care and what trials are available,” said Graiver. “ We are providing the patient connections and matching technology so that finding a trial becomes as straightforward as finding a flight. On Friday at DPharm, I will demonstrate how Antidote is building this breakthrough ecosystem to help speed up the development of new treatments and cures.”

Also an Executive Sponsor of the DPharm Conference, the company will be exhibiting its Antidote Match platform at Booth 35. Match leverages Antidote-structured eligibility criteria, proprietary algorithms, and machine learning to explore a patient’s eligibility for every trial. It currently powers clinical trial search for 180+ leading patient organizations to reach millions of patients per month. This year, Antidote has made its clinical trial matching platform accessible to the pharmaceutical industry with Match API, a web and mobile app layer that allows any organization to match patients to their portfolio or program of trials and build insights along the way.

Antidote has also just announced an $11M funding round led by Merck Global Health Innovation Fund (GHI), Merck’s venture investment arm, conditional upon certain regulatory clearances being obtained, and is expected…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *